Comparative Evaluation of Gemcabene and Peroxisome Proliferator–Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator–Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease

Gemcabene, a late-stage clinical candidate, has shown efficacy for LDL-C, non-HDL cholesterol, apoB, triglycerides, and hsCRP reduction, all risk factors for cardiovascular disease. In rodents, gemcabene showed changes in targets, including apoC-III, apoA-I, peroxisomal enzymes, considered regulated...

Descripción completa

Detalles Bibliográficos
Autores principales: Bisgaier, Charles L., Oniciu, Daniela C., Srivastava, Rai Ajit K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Cardiovascular Pharmacology 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039382/
https://www.ncbi.nlm.nih.gov/pubmed/29621036
http://dx.doi.org/10.1097/FJC.0000000000000580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039382/
https://www.ncbi.nlm.nih.gov/pubmed/29621036
http://dx.doi.org/10.1097/FJC.0000000000000580

Ejemplares similares